Chuck Royce's HALO Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 67,000 shares of Halozyme Therapeutics, Inc. (HALO) worth $4.51 M, representing 0.05% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Chuck Royce has maintained a strategic position in HALO, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2023, adding 139,310 shares. Largest reduction occurred in Q2 2025, reducing 119,612 shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's Halozyme Therapeutics (HALO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Halozyme Therapeutics (HALO) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -7,028 | Reduce 9.49% | 67,000 | $67.30 |
| Q3 2025 | -13,001 | Reduce 14.94% | 74,028 | $73.34 |
| Q2 2025 | -119,612 | Reduce 57.88% | 87,029 | $52.02 |
| Q1 2025 | +9,642 | Add 4.89% | 206,641 | $63.81 |
| Q4 2024 | +72,988 | Add 58.86% | 196,999 | $47.81 |
| Q3 2024 | -52,716 | Reduce 29.83% | 124,011 | $57.24 |
| Q2 2024 | -14,828 | Reduce 7.74% | 176,727 | $52.36 |
| Q1 2024 | +52,245 | Add 37.50% | 191,555 | $40.68 |
| Q4 2023 | +139,310 | New Buy | 139,310 | $36.96 |
| Q2 2023 | -45,000 | Sold Out | 0 | $0.00 |
| Q1 2023 | -51,000 | Reduce 53.12% | 45,000 | $38.19 |
| Q2 2022 | +64,000 | Add 200.00% | 96,000 | $44.00 |
| Q1 2022 | +32,000 | New Buy | 32,000 | $39.88 |
| Q3 2014 | -1,200 | Sold Out | 0 | $0.00 |
| Q2 2014 | -64,875 | Reduce 98.18% | 1,200 | $10.00 |
| Q1 2014 | -46,622 | Reduce 41.37% | 66,075 | $12.70 |
| Q4 2013 | -35,000 | Reduce 23.70% | 112,697 | $14.99 |
| Q3 2013 | +64,075 | Add 76.62% | 147,697 | $11.04 |
| Q2 2013 | +83,622 | Add 0.00% | 83,622 | $7.94 |
Chuck Royce's Halozyme Therapeutics Investment FAQs
Chuck Royce first purchased Halozyme Therapeutics, Inc. (HALO) in Q2 2013, acquiring 83,622 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held Halozyme Therapeutics, Inc. (HALO) for 21 quarters since Q2 2013.
Chuck Royce's largest addition to Halozyme Therapeutics, Inc. (HALO) was in Q4 2023, adding 139,310 shares worth $5.15 M.
According to the latest 13F filing for Q4 2025, Chuck Royce's firm, Royce & Associates Lp, owns 67,000 shares of Halozyme Therapeutics, Inc. (HALO), valued at approximately $4.51 M.
As of the Q4 2025 filing, Halozyme Therapeutics, Inc. (HALO) represents approximately 0.05% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in Halozyme Therapeutics, Inc. (HALO) was 206,641 shares, as reported at the end of Q1 2025.